{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:40:09Z","timestamp":1768927209508,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To our knowledge, data on comparison\u00a0of myo\u2010inositol and metformin\u00a0on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (<jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content>) are limited. This study was carried out to compare myo\u2010inositol and metformin on clinical, metabolic and genetic parameters in subjects with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, patients and measurements:<\/jats:title><jats:p>This randomized controlled trial was conducted among 60 subjects with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> aged 18\u201040\u00a0years. Subjects were randomly allocated into two groups to receive either myo\u2010inositol (N=30) or metformin (N=30) for 12\u00a0weeks. Gene expression of inflammatory cytokines was assessed in peripheral blood mononuclear cells (<jats:styled-content style=\"fixed-case\">PBMC<\/jats:styled-content>s) of <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> women by <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After the 12\u2010week intervention, compared with metformin, myo\u2010inositol intake significantly decreased serum total testosterone (\u22121.4\u00b14.2 vs +0.7\u00b11.4\u00a0nmol\/L, <jats:italic>P<\/jats:italic>=.03), modified Ferriman\u2010Gallwey (<jats:styled-content style=\"fixed-case\">mF<\/jats:styled-content>\u2010G) scores (\u22121.1\u00b10.7 vs \u22120.5\u00b10.8, <jats:italic>P<\/jats:italic>=.01) and serum high\u2010sensitivity C\u2010reactive protein (hs\u2010<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content>) levels (\u22122.6\u00b13.9 vs +0.2\u00b11.5\u00a0mg\/L, <jats:italic>P<\/jats:italic>&lt;.001). <jats:styled-content style=\"fixed-case\">RT<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> demonstrated that compared with metformin, myo\u2010inositol downregulated gene expression of interleukin\u20101 (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20101) (<jats:italic>P<\/jats:italic>=.02) in <jats:styled-content style=\"fixed-case\">PBMC<\/jats:styled-content>s of subjects with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content>. We did not observe any significant effect of myo\u2010inositol intake compared with metformin on other hormonal profiles, plasma nitric oxide (<jats:styled-content style=\"fixed-case\">NO<\/jats:styled-content>) or gene expression of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20108 and tumour necrosis factor alpha (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, taking myo\u2010inositol, compared with metformin, for 12\u00a0weeks in patients with <jats:styled-content style=\"fixed-case\">PCOS<\/jats:styled-content> with hyperinsulinism and normoinsulinism had beneficial effects on total testosterone, <jats:styled-content style=\"fixed-case\">mFG<\/jats:styled-content> scores, serum hs\u2010<jats:styled-content style=\"fixed-case\">CRP<\/jats:styled-content> levels and gene expression of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20101, but did not affect other hormonal profiles, <jats:styled-content style=\"fixed-case\">NO<\/jats:styled-content> levels or gene expression of <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u20108 and <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u2010\u03b1.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.13366","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T08:11:56Z","timestamp":1494317516000},"page":"194-200","source":"Crossref","is-referenced-by-count":28,"title":["<i>Expression of Concern<\/i>: Comparison of myo\u2010inositol and metformin\u00a0on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial"],"prefix":"10.1111","volume":"87","author":[{"given":"Mehri","family":"Jamilian","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Research Center Arak University of Medical Sciences  Arak Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pegah","family":"Farhat","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Research Center Arak University of Medical Sciences  Arak Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Foroozanfard","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics School of Medicine Kashan University of Medical Sciences  Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faraneh","family":"Afshar Ebrahimi","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics School of Medicine Kashan University of Medical Sciences  Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmat","family":"Aghadavod","sequence":"additional","affiliation":[{"name":"Research Center for Biochemistry and Nutrition in Metabolic Diseases Kashan University of Medical Sciences  Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Bahmani","sequence":"additional","affiliation":[{"name":"Research Center for Biochemistry and Nutrition in Metabolic Diseases Kashan University of Medical Sciences  Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Badehnoosh","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics School of Medicine Alborz University of Medical Sciences  Karaj Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Jamilian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Arak University of Medical Sciences  Arak Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-7224","authenticated-orcid":false,"given":"Zatollah","family":"Asemi","sequence":"additional","affiliation":[{"name":"Research Center for Biochemistry and Nutrition in Metabolic Diseases Kashan University of Medical Sciences  Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"545","article-title":"Metabolic consequences of polycystic ovary syndrome","volume":"67","author":"Churchill SJ","year":"2015","journal-title":"Minerva Ginecol"},{"key":"e_1_2_9_3_1","first-page":"551","article-title":"Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome","volume":"15","author":"Mansour A","year":"2016","journal-title":"EXCLI J"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.5910"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.11.023"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-200306000-00011"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0030"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018812437355"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2012.685205"},{"key":"e_1_2_9_10_1","first-page":"987","article-title":"Influence of inositol hexaphosphate on the expression of selected proliferation markers in IL\u20101beta\u2010stimulated intestinal epithelial cells","volume":"71","author":"Kapral M","year":"2014","journal-title":"Acta Pol Pharm"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590801893232"},{"key":"e_1_2_9_12_1","first-page":"347","article-title":"Randomized, double blind placebo\u2010controlled trial: effects of myo\u2010inositol on ovarian function and metabolic factors in women with PCOS","volume":"11","author":"Gerli S","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-1353"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.335539"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2016.1236078"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(81)90746-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.12.011"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.171"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2015.10.001"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.09.015"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12840"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.6.1591"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2012.743020"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590903015544"},{"key":"e_1_2_9_25_1","first-page":"105","article-title":"Metabolic and hormonal effects of myo\u2010inositol in women with polycystic ovary syndrome: a double\u2010blind trial","volume":"13","author":"Costantino D","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2011.564685"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3204083"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0840"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12451"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep37486"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.5604\/17322693.1014655"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-08-0524"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0924"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.1586"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2437"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-014-0307-z"}],"updated-by":[{"DOI":"10.1111\/cen.14889","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"record-id":"43984"},{"DOI":"10.1111\/cen.14889","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000}}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.13366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.13366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.13366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.13366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T14:09:14Z","timestamp":1692367754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.13366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/cen.13366"],"URL":"https:\/\/doi.org\/10.1111\/cen.13366","archive":["Portico"],"relation":{"expression_of_concern":[{"id-type":"doi","id":"10.1111\/cen.14889","asserted-by":"object"}]},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}